GlobeNewswire

Record gold sales in the first quarter of 2018 high grade intercepts in the Guiro mine.

Dela

QUÉBEC CITY, April 11, 2018 (GLOBE NEWSWIRE) -- Komet Resources Inc. is delighted to have generated record gold sales of CA$1,354,000 in the first quarter of 2018, with a production cash cost of CA$1,038,000 for 27.5 kilos of gold from the Guiro mine located in Burkina Faso. This occurs after only two quarters of operation since the active start of the optimized process. The modernization of the Guiro plant was completed at the end of the second quarter 2017, with, among other things, the installation of an Acacia intensive leaching reactor, the establishment of an in-series triple gravity concentrator system, the refurbishment of a larger capacity ball mill with a larger capacity and the installation of a hydrocyclone to operate in closed circuit mode.

Recent Development at the Guiro Mine

The company has recently obtained the results of eight diamond drill holes conducted as part of the ongoing resource development of the Guiro mine in Burkina Faso (see table below). These include the following intersections: 0.68 m grading 180.50 g/t Au in borehole Gu2017dd05, 1.24 m grading 10.36 g/t Au in borehole Gu2017dd03 and 1.68 m grading 17.11 g/t Au in borehole Gu2017dd06. Gu2017dd04 borehole also intercepted mineralization below the 4-east level in the mine, 12.5 meters west to the previously known Gu2015dd16 hole of 4.3 m grading 9.2 g/t. The results of this survey confirm the continuity of the vein as defined in the published NI43-101 resource calculation. Mining planning will be in this way better defined. The experience in the Guiro mine allows us to give an influence of 12.5 meters on both sides of a hole. Future development in this area then allows us to plan more than 7,100 t at 7.79 g/t Auundiluted. The vein is still open at least toward the west and at depth.

Furthermore, the Gu2017dd06 borehole located between two previously mined stopes on level 2, confirms a hitherto unknown continuity due to inaccessibility. This will allow us to mine more than 1000 t at 17.11 g/t Au undiluted. This excellent result will be followed by verification of the upper vertical continuity of level 2 in this new mineralized horizon.

These results follow those on the west development of the mine, announced in the January 29, 2018, press release.

Ongoing development

Komet's team is pursuing development westward at level 3 to reach the western gold ore shoot and aims in particular to join, within 30 m, the strike of the previously announced Gu2015dd35 drill intersection (1.4 m at 31 g/t Au). The development to the east at level 4 is also underway to complete the 25 meters required to reach the mineralization mentioned above. At the junction of level 3, a total of 35 m out of the planned 70m north development is underway and will allow reaching a mineralized zone parallel to the Guiro vein, mentioned in historical works, and allow positioning of the new pneumatic drill (Bazooka) for exploration at depth of the Guiro vein.

Finally, at the main shaft intersection at level 4, the development of a gallery is in progress in order to reach the parallel vein named "Guiro Sud" which gave results by core drilling such as 57 cm at 10.62 g/t Au and 52 cm at 8.64 g/t Au. See the May 25, 2017, press release for more information.

Mr André Gagné, president and CEO stated: "The development of the Guiro mine, as well as the nearby discoveries, confirm the excellent gold potential within our reach. In addition, the good gold sales results of the first quarter confirm the company's vision: 'Discovering by producing!'"

Summary table of drilling results:

Hole number From (m) To (m) Interval (m) True width (m) Au (g/t)
Gu2017dd01 161.00 162.65 2.65 1.43 1.22
incl 161.00 161.75 0.75 0.65 2.09
incl 162.45 162.65 0.20 0.17 1.96
Gu2017dd03 167.20 168.44 1.24 1.07 10.36
incl 167.70 168.44 0.74 0.64 16.73
Gu2017dd04 154.38 159.00 4.62 4.00 1.47
incl 155.00 155.38 0.38 0.33 7.32
Gu2017dd05 58.82 60.65 1.83 1.58 67.58
incl 59.32 60.00 0.68 0.59 180.50
Gu2017dd06 73.95 75.63 1.68 1.45 17.11
incl 73.95 74.50 0.55 0.48 13.12
incl 74.50 74.88 0.38 0.33 7.05
incl 74.88 75.63 0.75 0.65 25.13

The samples assays reported were obtained by standard 30 grams fire-assaying-AA finish or gravimetric finish at the Company's mine site laboratory and by plating on 50 g aliquots with atomic absorption (ppm for gold) at BIGGS Global in Burkina Faso. Sampling and supervision of the works were carried out on the site by qualified technicians. Quality assurance and quality control program and interpretation of results are done by qualified geologists according to a 43-101 compliant QA / QC program and industry best practices, including the introduction of samples reference, sterile samples and duplicates for each batch of 20 samples analyzed.

More information about the corporation is available at: http://kometgold.com.

Investors relations and information: 
André Gagné, President and CEO / +1-581-300-1666 / a.gagne@kometgold.com / Skype: andregagne11

Relations Publiques Paradox Inc. / Carl Desjardins / +1-514-341-0408 / carldesjardins@paradox-pr.ca

Jacques Marchand, P.Eng. P.Geo., is the Qualified Person who has reviewed this news release and is responsible for the geological information presented herein.

Forward-Looking Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute "forward-looking information" or "forward-looking statements" as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet's control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavorable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet's management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/0f952ff1-87ac-454d-a02f-9df5fbedf5db




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Komet Resources Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum